Me. Jonhagen et al., INTRACEREBROVENTRICULAR INFUSION OF NERVE GROWTH-FACTOR IN 3 PATIENTSWITH ALZHEIMERS-DISEASE, Dementia and geriatric cognitive disorders, 9(5), 1998, pp. 246-257
Nerve growth factor (NGF) is important for the survival and maintenanc
e of central cholinergic neurons, a signalling system impaired in Alzh
eimer's disease, We have treated 3 patients with Alzheimer's disease w
ith a total of 6.6 mg NGF administered continuously into the lateral c
erebral ventricle for 3 months in the first 2 patients and a total of
0.55 mg for 3 shorter periods in the third patient, The patients were
extensively evaluated with clinical, neuropsychological, neurophysiolo
gical and neuroradiological techniques, Three months after the NGF tre
atment ended, a significant increase in nicotine binding was found in
several brain areas in the first 2 patients and in the hippocampus in
the third patient as studied by positron emission tomography. A clear
cognitive amelioration could not be demonstrated, although a few neuro
psychology tests showed slight improvements, The amount of slow-wave c
ortical activity as studied by electroencephalography was reduced in t
he first 2 patients. Two negative side effects occurred with NGF treat
ment: first, a dull, constant back pain was observed in all 3 patients
, which in 1 patient was aggravated by axial loading resulting in shar
p, shooting pain of short duration, When stopping the NGF infusion, th
e pain disappeared within a couple of days, Reducing the dose of NGF l
essened the pain. Secondly, a marked weight reduction during the infus
ion with a clear weight gain after ending the infusion was seen in the
first 2 patients. We conclude from this limited trial that, while lon
g-term intracerebroventricular NGF administration may cause certain po
tentially beneficial effects, the intraventricular route of administra
tion is also associated with negative side effects that appear to outw
eigh the positive effects of the present protocol, Alternative routes
of administration, and/or lower doses of NGF, perhaps combined with lo
w doses of other neurotrophic factors, may shift this balance in favor
of positive effects.